Capmatinib delivers rapid disease control in MET exon 14 skipping lung cancer, yet durability is bounded by a set of escape routes that are now well catalogued. Because those routes are predictable, the sensible practice is to define the next line before a scan confirms progression rather than improvising afterwards.
Available as 150 mg and 200 mg tablets in a 56-tablet presentation, the product also matches the Tabrecta reference pack familiar to prescribers.
Exon 14 of the MET gene encodes a juxtamembrane segment containing the binding site through which the receptor is normally tagged for degradation. When splicing skips that exon, the segment disappears, the receptor escapes routine disposal, and signalling continues far longer than it should. Capmatinib is a highly selective type Ib inhibitor that competes for the ATP pocket of the MET kinase domain and shuts that prolonged signalling down.
Escape follows two broad patterns. On-target substitutions in the kinase domain, notably at residues D1228 and Y1230, reshape the pocket so a type Ib molecule no longer binds well. Alternatively, tumours activate a parallel receptor route — EGFR, HER3 or amplified KRAS — leaving MET inhibited yet irrelevant.
Adults with metastatic non-small cell lung cancer whose tumours carry an alteration causing MET exon 14 skipping are eligible, with the alteration confirmed by a validated assay before treatment. Detection commonly relies on RNA-based sequencing, which reads the skipped transcript directly and avoids missing the diverse DNA-level splice-site variants that produce the same result.
The standard schedule is 400 mg twice daily, taken as two 200 mg tablets morning and evening, with or without food, continued while benefit persists. The 150 mg strength supports the stepwise reductions used for interstitial lung disease, hepatotoxicity or peripheral oedema, moving to 300 mg and then 200 mg twice daily. Physicians adjust according to tolerance.
Tablets are kept at controlled room temperature in the original container, without refrigeration. Pack arithmetic deserves attention: at four tablets a day, a 56-tablet pack covers fourteen days, so a patient on the standard dose needs two packs per month and any reorder cycle built around a single monthly pack will run short. Stocking both strengths is advisable, since dose reductions are common enough that a 150 mg supply is regularly required at short notice.
Q: Which secondary kinase-domain substitutions blunt capmatinib activity?
A: Changes at residues such as D1228 and Y1230 alter the ATP pocket so that a type Ib inhibitor binds far less effectively.
Q: Is switching inhibitor class worthwhile once on-target resistance appears?
A: Type II MET inhibitors engage the pocket differently and can retain activity against some of these substitutions, which is why identifying the specific change matters.
Q: Does one 56-tablet pack cover a full month at the standard dose?
A: No. Four tablets daily consume the pack in fourteen days, so two packs per patient month are required.
Q: Which assay best confirms exon 14 skipping before therapy begins?
A: RNA-based sequencing reads the skipped transcript directly, capturing variants that DNA-only panels can miss.
Capmatinib delivers rapid disease control in MET exon 14 skipping lung cancer, yet durability is bounded by a set of escape routes that are now well catalogued. Because those routes are predictable, the sensible practice is to define the next line before a scan confirms progression rather than improvising afterwards.
Available as 150 mg and 200 mg tablets in a 56-tablet presentation, the product also matches the Tabrecta reference pack familiar to prescribers.
Exon 14 of the MET gene encodes a juxtamembrane segment containing the binding site through which the receptor is normally tagged for degradation. When splicing skips that exon, the segment disappears, the receptor escapes routine disposal, and signalling continues far longer than it should. Capmatinib is a highly selective type Ib inhibitor that competes for the ATP pocket of the MET kinase domain and shuts that prolonged signalling down.
Escape follows two broad patterns. On-target substitutions in the kinase domain, notably at residues D1228 and Y1230, reshape the pocket so a type Ib molecule no longer binds well. Alternatively, tumours activate a parallel receptor route — EGFR, HER3 or amplified KRAS — leaving MET inhibited yet irrelevant.
Adults with metastatic non-small cell lung cancer whose tumours carry an alteration causing MET exon 14 skipping are eligible, with the alteration confirmed by a validated assay before treatment. Detection commonly relies on RNA-based sequencing, which reads the skipped transcript directly and avoids missing the diverse DNA-level splice-site variants that produce the same result.
The standard schedule is 400 mg twice daily, taken as two 200 mg tablets morning and evening, with or without food, continued while benefit persists. The 150 mg strength supports the stepwise reductions used for interstitial lung disease, hepatotoxicity or peripheral oedema, moving to 300 mg and then 200 mg twice daily. Physicians adjust according to tolerance.
Tablets are kept at controlled room temperature in the original container, without refrigeration. Pack arithmetic deserves attention: at four tablets a day, a 56-tablet pack covers fourteen days, so a patient on the standard dose needs two packs per month and any reorder cycle built around a single monthly pack will run short. Stocking both strengths is advisable, since dose reductions are common enough that a 150 mg supply is regularly required at short notice.
Q: Which secondary kinase-domain substitutions blunt capmatinib activity?
A: Changes at residues such as D1228 and Y1230 alter the ATP pocket so that a type Ib inhibitor binds far less effectively.
Q: Is switching inhibitor class worthwhile once on-target resistance appears?
A: Type II MET inhibitors engage the pocket differently and can retain activity against some of these substitutions, which is why identifying the specific change matters.
Q: Does one 56-tablet pack cover a full month at the standard dose?
A: No. Four tablets daily consume the pack in fourteen days, so two packs per patient month are required.
Q: Which assay best confirms exon 14 skipping before therapy begins?
A: RNA-based sequencing reads the skipped transcript directly, capturing variants that DNA-only panels can miss.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
